Abstract: The present invention provides a method for treating or preventing certain metabolic disorders comprising the systemic administration of 3-guanidinopropionic acid.

Abstract: The present invention provides novel substituted 2-[monoannelated(3,4- 4,5-, and 5,6-)pyridylalkylenesulfinyl]-benzimidazoles with gastric acid inhibiting effects.

Abstract: This invention relates to the method for treating human baldness, including the form of alopecia commonly known as "male pattern baldness", which comprises regular topical application to the affected areas of the human scalp of minoxidil and an anti-inflammatory agent.

Abstract: The present invention provides novel renin-inhibiting peptides of the formula X-A.sub.6 -B.sub.5 -C.sub.8 -D.sub.9 -E.sub.10 -F.sub.11 -G.sub.12 -H.sub.13 -I.sub.14 -Z, wherein X and Z are terminal groups, C.sub.8 contains S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid, and 3-(arylthio)alkyl moieties, and the remaining variables are amino acid residues. Such inhibitors are useful for the diagnosis and control of renin-dependent hypertension.

Abstract: The present invention provides novel 3'-pyridinylalkenylindole-2-carboxylic acids and derivatives thereof of the formulas I and II ##STR1## which are useful as thromboxane A.sub.2 (TXA.sub.2) synthetase inhibitors and as such represent potent pharmacological agents.

Abstract: The present invention provides novel renin inhibitory peptides of the formula X--A--B--C--D--E--F--G--H--Z wherein E--F is a dihalo-substituted statine group, X and Z are terminal groups, and the remaining variables are absent or amino acid residues. These compounds are useful for administration to humans to treat hypertension.

Abstract: The present invention provides novel renin-inhibiting peptides and novel processes and intermediates for the preparation of both novel and known renin-inhibiting peptide analogs. Such inhibitors are useful for the diagnosis and control of renin-dependent hypertension.

Abstract: The present invention provides novel N-substituted derivatives 2-(pyridylalkylenesulfinyl)benzimidazoles with gastric acid inhibiting effects.

Abstract: The present invention provides novel renin-inhibiting peptides of the formula X-A.sub.6 -B.sub.7 -C.sub.8 -D.sub.9 -E.sub.10 -F.sub.11 -G.sub.12 -H.sub.13 - I.sub.14 -Z, wherein the E.sub.10 -F.sub.11 moiety is a dihydroxyethylene isostere, X and Z are terminal groups, and the remaining variables are absent or are amino acid residues. Such inhibitors are useful for the control of hypertension.

Abstract: The present invention provides novel pyridinyl- benzothiophenes and derivatives thereof which are useful as thromboxane A.sub.2 (TXA.sub.2) synthetase inhibitors and as such represent potent pharmacological agents.

Abstract: A method for reducing dysfunction in angioplasty procedures and particularly, in myocardial angioplasty procedures in human beings is desired. The method involves the introduction of a selected amount of intra-arterial prostaglandin compound into an artery, such as a coronary artery, in which an angioplasty procedure is to occur. The prostaglandin compound will provide cyto-protection and provide antithrombotic effects and antiplatelet effects and antispasmatic effects. The prostaglandin compound is administered in a pharmacological amount, that is, an amount substantially greater than the prostaglandin which would be generated by a normal myocardial artery when insulated and thus, constitutes an administration substantially greater than an amount which would be administered in a replacement therapy.

Abstract: The present invention provides a novel methoda for preventing deep vein thrombosis comprising the administration of lipoxygenase inhibitors of Formula I ##STR1##

Abstract: The present invention provides novel 3'-pyridinylalkenylindole-2-carboxylic acids and derivatives thereof of the formula I and II ##STR1## which are useful as thromboxane A.sub.2 (TXA.sub.2) synthetase inhibitors and as such represent potent pharmacological agents.

Abstract: The present invention provides a novel process for reducing 15-keto prostaglandin intermediates. This process stereospecifically reduces these 15-keto intermediates using sodium borohydride and ceriumtrichloride, yielding a predominance of the 15.alpha. epimer.

Abstract: Prostacyclin (PGI.sub.2) analogs having a 6a-carba feature, for example a compound of the formula ##STR1## said analogs having pharmacological activity. Processes for preparing them and the appropriate intermediates are disclosed.

Abstract: Crystalline, non-hygroscopic adinazolam methanesulfonate, per se, preparable from xylene or preferably from a C.sub.1 to C.sub.2 -alkanol/C.sub.4 to C.sub.6 -alkyl acetate liquid mixture, aids processability of adinazolam methanesulfonate in pharmaceutical production plants.

Abstract: The present invention provides a novel method for treating osteoporoses, joint and dental diseases and increasing the rate of bone healing by orally administering certain prostaglandins. Further provided are novel compositions employing these prostaglandins.

Abstract: The present invention provides substituted 2-pyridylmethylthio- and sulfinyl-benzimidazoles with gastric acid inhibiting effects.

Abstract: The present invention particularly provides novel furochromones and intermediates for their preparation.

Abstract: New and potent antineoplastic agents designated bryostatin 4, bryostatin 5, bryostatin 6, bryostatin 7, and bryostatin 8 have been isolated from the marine animal Bugula neritina L. and Amatnea convoluta (Bryozoan phylum).